POSIÇÃO BRASILEIRA PARA A 3ª REUNIÃO DO GRUPO INTERGOVERNAMENTAL
AD HOC DO CODEX SOBRE ALIMENTOS DERIVADOS DA BIOTECNOLOGIA
(YOKOHAMA, JAPÃO, 04 - 08/03/2002)

TEMA 1 - CX/FBT 02/1 - Adoção da Agenda

Posição Brasileira: Nada a comentar.

TEMA 2 - CX/FBT 02/2 - Assuntos remetidos pela Comissão do Codex e Outros Comitês

Posição Brasileira: Nada a comentar.

TEMA 3 - CX/FBT 02/3 - Assuntos de Interesses de Outras Organizações Internacionais em que Respeita a Avaliação dos Aspectos da Inocuidade e Valor Nutricional de Alimentos Obtidos Através da Biotecnologia.

Posição Brasileira: Nada a comentar.

TEMA 4 - ALINORM 01/34 A, Apêndice II - Exames do Projeto de Princípios para a Análises de Riscos sobre Alimentos Obtidos Através da Biotecnologia Moderna (Trâmite 7)
  - CX/FBT 02/4 - Observações dos Governos, no Trâmite 6

Posição Brasileira: A Delegação Brasileira deve se posicionar em sintonia com a manifestação do Brasil em outros Comitês do Codex, particularmente o de Princípios Gerais. Neste Comitê o tema - Princípios de Trabalhos para Análise de Riscos está no Trâmite 3 e a última posição adotada pelo Brasil em relação ao documento encontra-se em anexo. O documento CX/GP 02/3 é a última versão do tema que será discutida na reunião do CCGP em abril de 2002.

TEMA 5 - A) ALINORM 01/34 A Apêndice III - Exames do Projeto de Diretrizes para a Realização da Avaliação da Inocuidade Princípios para a Análises de Riscos sobre Alimentos Obtidos de Plantas de DNA Recombinante, no Trâmite 7

    - CX/FBT 02/5 - Observações dos Governos, no Trâmite 6 (CL 2001/28-FBT)
    - CL 2001/38-FBT Anexo II - Projeto de Texto Revisado na Seção "Avaliação da Possível Toxicidade" do Projeto de Diretrizes para a Realização da Avaliação da Inocuidade de Alimentos Obtidos de Plantas de DNA Recombinante
    - CL 2001/38-FBT Anexo III - Respostas as Perguntas da Presidência do Grupo de Ação Apresentadas para Exame pelo Grupo de Trabalho
    - CX/FBT 02/5 Add.1 - Observações dos Governos sobre os Dois Documentos, em Trâmite 6 (CL 2001/38-FBT, Anexos II e III)
    - CX/FBT 02/4 - Observações dos Governos, no Trâmite 6

Posição Brasileira: O Brasil encaminhou resposta, por escrito, ao Secretariado do Codex e ao Secretariado do Grupo Ad Hoc ao documento CL 2001/38 - FBT, conforme consta em anexo a presente Posição Brasileira.

B) CL 2001/38-FBT, Anexo I - Exame do Anteprojeto de Anexo sobre a Avaliação da Alergenicidade do Projeto de Diretrizes para a Realização da Avaliação da Inocuidade de Alimentos Obtidos de Plantas de DNA Recombinante, no Trâmite 4

    - CX/FBT 02/6 - Observações dos Governos , no Trâmite 3

Comentários: O GT - FBT, do Comitê do Codex Alimentarius do Brasil - CCAB, se reuniu e apresentou os seguintes comentários e proposta de Posição Brasileira, como segue:

  • O Dr. Hoeck Miranda, técnico da ANVISA, propôs que a Delegação Brasileira não assumisse qualquer posição quanto ao número de aminoácidos - AA a serem considerados - 6 ou 8, pelo fato de que o assunto ainda está em estudo, levando-se em conta que os riscos à saúde pública são teoricamente maiores quando a análise de Alergenicidade é realizada com base na seqüência de 8 AA.

  • Entretanto, o argumento do grupo foi baseado nas posições dos Consultores ad hoc Luiz Querino e Beni Olej e no documento derivado da reunião "Ad hoc Open-Ended Working Group on Allergenicity", de setembro de 2001, no qual, na página 6, na nota de rodapé, é citado que " It is recognized that the 2001 FAO/WHO consultation suggested moving from 8 to 6...", concluindo que a posição atual, em vigor, é a de 8 aminoácidos.
  • Após discussões, houve consenso do grupo quanto a orientação aprovada de que o Brasil deverá exigir um estudo mais detalhado sobre o assunto, mas que concorda em manter, temporariamente, a base de estudo em 8 aminoácidos. Esta posição é de cautela, até que se obtenha uma maior base científica, já que na mesma nota citada, é dito que "uma seqüência menor aumenta o número de falsos positivos, enquanto a seqüência maior aumenta o número de falsos negativos", não chegando-se ainda a uma definição.

Posição Brasileira: O Brasil encaminhou resposta, por escrito, ao Secretariado do Codex e ao Secretariado do Grupo Ad Hoc ao documento CL 2001/38 - FBT, conforme consta em anexo a presente Posição Brasileira.

TEMA 6 - CX/FBT 02/7 - Exame do Anteprojeto de Diretrizes para Avaliar a Inocuidade de Alimentos Obtidos de Microorganismos de DNA Recombinante utilizados nos Alimentos, no Trâmite 4

    - CX/FBT 02/7 Add.1 - Observações dos Governos, no Trâmite 3

Posição Brasileira: O Brasil encaminhou resposta, por escrito, ao Secretariado do Codex e ao Secretariado do Grupo Ad Hoc ao documento CL 2001/46 - FBT, conforme consta em anexo a presente Posição Brasileira.

TEMA 7 - CL 2001/27-FBT - Documento de Debate sobre Rastreabilidade
- CX/FBT 02/8 - Observações dos Governos

Comentários: O GT - FBT, do Comitê do Codex Alimentarius do Brasil - CCAB, se reuniu e apresentou os seguintes comentários e proposta de Posição Brasileira, como segue:

  • A posição brasileira preparada pelo Grupo, reitera que o tema Rastreabilidade não deve ser visto como um item da Análise de Risco, mas sim como dados documentais referentes ao alimento a ser comercializado, de modo a garantir o direito a informação do consumidor. Ademais, os dados gerados no processo de Rastreabilidade servem como base para estudos, quando houver algum risco que represente uma ameaça à saúde pública. O GT-FBT entendeu e endossou a posição encaminhada anteriormente ao CCAB e aprovada como posição brasileira.

Posição Brasileira: O Brasil encaminhou resposta, por escrito, ao Secretariado do Codex e ao Secretariado do Grupo Ad Hoc ao documento CL 2001/27 - FBT, conforme consta em anexo a presente Posição Brasileira.

TEMA 8 - CX/FBT 02/9 - Exame de Métodos de Análises

Comentários: O GT - FBT, do Comitê do Codex Alimentarius do Brasil - CCAB, se reuniu e apresentou os seguintes comentários e proposta de Posição Brasileira, como segue:

  • O documento em questão é um informe dos países participantes sobre metodologias adotadas para a análise do material genético de organismos modificados. Alguns países participantes forneceram informações sobre o estado da Arte no que concerne a sua capacidade para realizar análises qualitativas e quantitativas de OGMs;

  • É preciso também que o Codex acelere os seus trabalhos junto a validação dos Métodos Analíticos, principalmente com relação aos quantitativos e que seja montado para isso um Plano de Amostragem o qual deva ser seguido como padrão;
  • Será solicitado ao GT-Métodos Analíticos, do CCAB, coordenado pela Dra. Paola/INCQS, as seguintes questões:
    1. O GT defina uma posição quanto ao estudo interlaboratorial para padronização dos métodos de análise qualitativa, para que se possa avançar na implantação da análise semi-quantitativa.;
    2. Ficou acordado que o Brasil deveria demonstrar sua preocupação no sentido de dominar tais metodologias de modo a obter credenciamento internacional para organizar uma rede de laboratórios nacionais com esse objetivo;
    3. Estender o processo de análise para outras regiões do país, principalmente ao Nordeste, e incluir laboratórios desta região, que possui grupos capacitados no processo de detecção por PCR, principalmente em centros como Alagoas, Natal e Recife;
    4. Inclusão de outras técnicas, dentre as quais MALDI e espectro de massa, de rápida e confiável detecção.

Posição Brasileira: A Delegação Brasileira deverá acompanhar atentamente as discussões, seguindo os comentários acima expostos; e poderá sugerir ao GT-MAS/FBT que ao encaminhar seus trabalhos ao CCMAS, continue auxiliando o desenvolvimento dos mesmos no âmbito daquele Comitê do Codex, como grupo ad hoc, coordenado pelo Canadá.

TEMA 9 - Outros Assuntos, Trabalhos Futuros, Data e Local da Próxima Reunião

Posição Brasileira: Nada a comentar.

TEMA 10 -. Adoção do Informe

Posição Brasileira: Acompanhar a aprovação do Informe.


ANEXO A POSIÇÃO BRASILEIRA PARA A 3ª REUNIÃO DO GRUPO INTERGOVERNAMENTAL AD HOC DO CODEX SOBRE ALIMENTOS DERIVADOS DA BIOTECNOLOGIA

TEMA 4 - Resposta a CL 2001/24 - GP
BRAZIL COMMENTS ON CL 2001/24 - GP - DRAFT WORKING PRINCIPLES FOR RISK ANALYSIS

1. In the "Scope" Chapter, paragraph 2, Brazil suggests a new wording, with the inclusion of the text in brackets at paragraph 3. Paragraph 2 would then read as follows:

"The primary purpose for risk analysis in the Codex Alimentarius Commission is providing an objective basis for measures to protect the health of consumers while at the same time ensuring fair practices in the food trade."

Australia presented this amendment and Brazil supported it during the 16th Session of CCGP. Such proposal did not receive clear opposition. However, the Report of the Committee situated the amendment wrongly in the text. Brazil understands that the amendment, in the proposed paragraph, improves the text.

2. In the "Scope" Chapter, paragraph 3, Brazil suggests that, according to the previous suggestion, the text in brackets should be eliminated.

3. In the "Risk Analysis - General Aspects" Chapter, Brazil suggests to eliminate paragraph 10, since the Commission has already decided over the issue. Brazil understands that the term 'precaution' should not be used in the text, given the subjectivity it carries with it.

4. In the "Risk Analysis - General Aspects" Chapter, Brazil suggests to maintain paragraph 11 without the brackets. Brazil understands that this paragraph adequately contemplates the possible situations in a risk analysis process, namely the uncertainty.

5. In the Chapter "Risk Analysis - General Aspects", Brazil suggests to eliminate the subtitle "Risk Assessment Policy", since the later is not defined as a separated element of the risk analysis process. According to the FAO/WHO Consultation on Risk Management, the Risk Evaluation Policy is a component of "Risk Evaluation", which is part of Risk Management.

6. In the Chapter "Risk Analysis - General Aspects", Brazil suggests to eliminate paragraph 13, since its position would present a contradiction. Besides, the context in which the policy is inserted already appears in the definition of that Policy.

7. In the Chapter "Risk Analysis - General Aspects", Brazil suggests to eliminate paragraph 14 since a definition of the term "Risk Evaluation Policy" already exists in Annex 1.

8. In the Chapter "Risk Analysis - General Aspects", Brazil suggests to renumber paragraph 15 as paragraph 13 and to reorder the text as follows:

" To ensure that the risk assessment process is systematic, complete and transparent The risk assessment policy should be established by risk managers preferably in advance of risk assessment, in consultation with risk assessors and all other interested parties, in order to ensure that the risk assessment process is systematic, complete and transparent.

9. In the "Risk Analysis - General Aspects" Chapter, Brazil suggests to transfer paragraphs 16 and 17 to "Risk Management" Chapter and to locate it immediately after paragraph 39 of the current text.


POSIÇÃO BRASILEIRA PARA A 15ª REUNIÃO DO CCGP SOBRE O DOCUMENTO EM QUESTÃO, PARTICULARMENTE SOBRE O PRINCÍPIO/ENFOQUE DA PRECAUÇÃO.

1) CX/GP 00/3 - PRINCÍPIOS DE APLICAÇÃO PRÁTICA SOBRE ANÁLISE DE RISCOS
CX/GP 00/3 - Add.1 e Add. 3 - COMENTÁRIOS DOS GOVERNOS À CL - 1999/16-GP
CX/GP 00/3 - Add.2 - COMUNICAÇÃO DA COMISSÃO EUROPÉIA SOBRE PRINCÍPIO DA PRECAUÇÃO

Observação - 1: O Brasil encaminhou resposta à CL 1999/16 - GP, cujos comentários constam do documento CX/GP 00/3 - Add.1.

Posição Brasileira: A Delegação Brasileira deve parabenizar o Secretariado do Codex e o Comitê pela forma como analisaram e procuraram incorporar os comentários elaborados pelos países em resposta à CL 1999/16 - GP. Considerando o excelente trabalho realizado acreditamos que este exercício deve ser seguido pelos outros Comitês, pois auxilia os trabalhos durante a reunião.
Em relação ao documento CX/GP 00/3 o Brasil deseja apresentar comentários específicos sobre o princípio/enfoque da precaução e sobre os Princípios de Trabalho sobre Análise de Riscos.

I - COMENTÁRIOS SOBRE O PRINCÍPIO/ENFOQUE DA PRECAUÇÃO

No que se refere ao comércio internacional de alimentos o Brasil considera que toda a disciplina normativa necessária à defesa da saúde humana está prevista nos acordos em vigor, em particular no Acordo SPS da OMC. O Brasil ratifica a importância da utilização das normas e textos elaborados pelo Codex como referência internacional que, com base na ciência, buscam assegurar práticas leais de comércio. O Brasil entende que a introdução do princípio/enfoque da precaução, como sugerido, poderia representar contradição com os instrumentos internacionais existentes, uma vez que tenderia a estimular práticas protecionistas de comércio, sem o correspondente incremento da defesa da saúde humana. Nesse contexto, o debate deverá prosseguir antes de se adotar qualquer decisão a respeito do princípio, a fim de que se tenham claras as implicações de sua adoção.

No que concerne à aplicabilidade do princípio/enfoque da precaução no âmbito do Codex, particularmente na seção sobre gerenciamento de risco do documento em questão, o Brasil entende que, na ausência de evidência científica, seria temerário que o Codex e seus órgãos auxiliares possam estabelecer qualquer medida sob pena de ferir a 1ª Declaração de Princípio Relativa ao Papel da Ciência no Processo de Tomada de Decisão do Codex e, portanto, de não serem consistentes com seu papel de organismo normalizador internacional sob o Acordo SPS da OMC.

 


ANEXO A POSIÇÃO BRASILEIRA PARA A 3ª REUNIÃO DO GRUPO INTERGOVERNAMENTAL AD HOC DO CODEX SOBRE ALIMENTOS DERIVADOS DA BIOTECNOLOGIA

TEMA 5 - Resposta a CL 2001/38 - FBT

Comments of the Brazilian Delegation to CL 2001/38 - FBT
ANNEX I, II and III of ALINORM 01/34A

1 - Annex I
Assessment of Possible Allergenicity (Proteins)
Section 1 - Introduction

1. We suggest to clarify better the definition for "newly expressed protein", due to the fact that the conjugated proteins, such as glycoproteins and phosphoglycoproteins, have been identified and can act like potential allergens.
"According to Steve L. Taylor 1 "there is the existing possibility that other components of the food that can act as haptens".
1see paper Topic 1: Overview of Current Approach have determines the Allergenicity of Genetically Modified Foods (Steve L. Taylor) Joint FAO/WHO Expert Consultation on Foods derived from Biotechnology.
2 - According to Stryer, 1995, proteins, poliosides and nucleic acids are, in general, effective antigens. In their majority, the small strange molecules do not stimulate antibody formation. However, they can promote the formation of specific antibody if they are linked to macromolecules. The macromolecule is then the carreator of the linked chemical group, that is called determinant haptenic. The strange and small molecule is called hapten. The antibodies induced by haptens linked also react with haptens not linked. These organic, natural or synthetical molecules of low molecular mass (lower than 1 KDa), penetrate in the epidermis, they conjugate with proteins of the body and thus are carried. The joint hapten-carreator is called conjugated.

²Biochemistry. Lubert Stryer. Eds. W. H. Freedman and Company, New York, New York and Basingstoke, 1995.

Section 2 - Assessment Strategy

3. Include the phrase "and heat stability and/or, acid and enzymatic treatment" after "enzymatic degradation".
- Relative resistance to enzymatic and/or heat and acid treatment are physicochemical characteristics of known food allergens and should be considered in the Assessment Strategy.
- see: Ricki M. Helm. Topic 5: Stability of Known Allergens (Digestive and Heat Stability),. Joint FAO/WHO Expert Consultation on Foods Derived from Biotechnology and;
 - Kuiper, H.A., Kleter, G.A., Noteborn, H.P.J. and Kok, E.J. "Assessment of the safety issues related to genetically modified foods". The Plant Journal, 27 (6): 503-528, 2001.

Section 3 - Initial Assessment

Section 3.1 - Source of Protein

6. Include "such as physicochemical and immunological properties" after "structural characteristics and amino acid sequence" (...).
- There is a relationship among the physicochemical properties and the stability and the size of the protein;
- The immunological properties include immunogenicity and cross-reactivity.

See: Topic 3: Allergen Databases/Class of protein/Allergen function (Rob Aalberse) Joint FAO/WHO Expert Consultation on Foods derived from Biotechnology.

7. We agree with the previous recommendation proposed to Metcalfe et al. (1996); Hileman et al, (2001)( in press) to maintain that any match of 8 contiguous identical amino acids is a conservative yet appropriate criteria for such searches, until better understanding. According to Hileman et al, (2001), in a study reported with corn, it concludes that the analysis criterion for 6 identical amino acids would lead to the identification of 84 % of all the corn proteins as allergenic, a gross over-estimation. The results obtained by alignment by FASTA indicated that just 8 of the 50 existing proteins probably are homologous to one or more allergenic proteins. The data supports recommendation that any match of 8 contiguous identical amino acids is a conservative yet appropriate criterion for such searches. The additional FASTA search and the information regarding the probability of homology or the > 35% identify in any segment of 80 or more amino acids (FAO/WHO 2001).
- Metcalfe, D.D., J.D. Astwood, R. Townsend, H.A. Sampson, S.L. Taylor and R.L. Fuchs. "Assessment of the allergenic potential of foods from genetically engineered crop plants". Crit Rev Food Sci Nut, 36(S):S165-186, 1996.

- Hileman, R.E., Silvanovich, A., Astwood, J.D., Hefle, S.L. "A bioinformatics approach to the assessment of the allergenicity of foods produced through agricultural biotechnology. Adv. Food Nutr. Res., 2001 (In press).

Section 3.3 - Pepsin Resistance

12. Add to the item 12, after the last paragraph: "Simulated Intestinal Fluid assays (SIF) 2 with trypsin, chymotrypsin, carboxipeptidase enzymes should also be carried out.

Assessment of in vitro digestion with f others enzymes of the digestive tract has been described in USP1 (1990) and carried out by Fuchs et al 2, (1993) and Harrison et al3, (1996).

1 USP . The United States: Pharmacopeia, Vol XXII, NFXVII. United States Pharmacopeial Convention, Inc., Rockville, MD, 1990.

2 Fuchs, R. L., Ream, J. E., Hammond, B. G., Naylor, M. W., Leimgruber, R.M., & Berberich, S. A. Safety assessment of neomycin phophotransferase II (NPTII) protein. Biotechnology 11: 1543-1547, 1993.

3 Harrison, L.A., Bailey, M.R., Naylor, M.W., Ream, J.E., Hammond, B.G., Nida, D.L., Burnette, B.L., Nickson, T.E., Mitsky, T.A., Taylor,M.L., Fuchs, R.L. and Padgette, S.R. "The expressed protein in glyphosate-tolerant soybean, 5-enolypyruvylshikimate-3-phosphate synthase from Agrobacterium sp. Strain CP4, is rapidly digested in vitro and is not toxic to acutely gavaged mice". The Journal of Nutrition, 126 (3): 728-740, 1996.

- Also to include after the last paragraph of the item 12: Heat and acid treatment of newly expressed protein, should be considered and standardized, in case of food processing (at high temperatures) 1

1 see proposed Dr. Ricki M. Helm [Topic 5: Stability of Known Allergens (Digestive and Heat Stability), paper - Joint FAO/WHO Expert Consultation on Foods derived from Biotechnology).

Section 6 - Areas Requiring Further Development

17. We suggest the inclusion of the specific sub items in the section 6:
1 - Animal Models;
2 - Targeted serum screening;
3 - Other techniques such as T-cell epitopes and structural motifs.

2 - Annex II

"Proposed Revised text on entitled Assessment of Possible Toxicity from Proposed ...Recombinant DNA-PLANTS"

A. we suggest that the end of the sentence in boldface be changed for "...activity of enzymes originated by introduced DNA", because the expression "introduced enzymes" could induce to a deceitful comprehension that the enzyme is the one being introduced instead of the DNA.

B. we suggest the substitution of the sentence in boldface for "characteristic of newly expressed substance as well its concentration in edible parts ", since the term "function" is inadequate to express, for example, the toxicity potential of the substance and moreover, the composition involving the word "identify", together with the remaining of the sentence, is not sufficiently clear.

C. Replace "function" for "characteristic" as justified in paragraph B.

D. Replace "function" for "characteristic" as justified in paragraph B.

E. Replace "function" for "characteristic" as justified in paragraph B.


ANEXO A POSIÇÃO BRASILEIRA PARA A 3ª REUNIÃO DO GRUPO INTERGOVERNAMENTAL AD HOC DO CODEX SOBRE ALIMENTOS DERIVADOS DA BIOTECNOLOGIA

TEMA 6 - Resposta a CL 2001/46 - FBT

PROPOSED DRAFT GUIDELINE FOR THE CONDUCT OF FOOD SAFETY ASSESSMENT OF FOODS PRODUCED USING RECOMBINANT-DNA MICROORGANISMS

SECTION 1 - SCOPE

1. It is not mentioned in the scope that such foods or food ingredient could contain others components, or the new components produced by recombinant-DNA Microorganisms.

  • Paragraph 1, line 3, footnote 1: definition of the term microorganisms. For the purpose of the document, microorganisms are defined as bacteria, yeasts, and filamentous fungi. This definition may, according to interpretation, exclude groups which may also be considered microorganisms by some specialists, such as mushrooms (Basidiomycetes), which are widely used as food products in natura or may be used as ingredients in prepared foods, or even for the production/extraction of food additives, such as flavors and aromas (e.g., trufles). The current definition also excludes the microalgae, which, in certain cases, may be used as food additives (e.g., Chlorella). Genes from other microorganisms, such as Archaea, may be used, in the future, in food production. This definition should be broadened a little to accommodate these.
     

  • The Brazilian Delegation also would like to request explanation if the Scope of this Guideline has been applied only to the microorganisms "per se", or food produced using recombinant-DNA Microorganisms, such as filamentous fungi (mushrooms-Basidiomycetes).
     
  • Paragraph 7: Term "microflora" should be replaced by "microbiota", because with the modern taxonomic classification, fungi and bacteria are not included to the plant kingdon.
     
  • The distribution of the normal microbiota is very variable on the human body. It has been reported a resident and transient microbiota in/on human body which should be considered in this annex. We must be aware that the microbiota in mouth, oropharynx, stomach, small and large intestine, skin, eye (conjuctiva), nose, etc are completely distinct and should be carefully evaluated.

4. Sub-item 4D): replace, in all documents, the gastrointestinal "microflora" by "microbiota".

7. In order to clarify the first paragraph of the item 7, it is necessary to add as footnote, the wide acceptable variability in the analytical differences (recombinant DNA microorgamism and conventional counterpart) could be found between the parental and the recombinant strains evaluated.

SECTION 2 - DEFINITIONS

Paragraph 8: Definition of "recombinant-DNA microorganism" is broader than the definition of "genetically modified organism" (GMO), and includes organisms that are produced by in vitro methods; but seems to exclude from this definition those derived from classical genetic manipulation methods, such as random and directed mutagenesis, deletions and gene knock-outs, directed evolution, and protoplast fusion with organisms from other species or with other strains of the same species. All these later methods can produce recombinant-DNA microorganisms with equal risk potential as transgenic and the in vitro methods cited. We suggest that the part of "recombinant-DNA microorganism" definition - "including recombinant deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cell organelles" - should be removed because these techniques have been defined in the footnote of the same page.

  • Definition of "conventional counterpart" is need to refined to clearly define that the conventional counterpart should be as close as possible to the modified microorganism/strain under testing, so that the risk assessment process may be considered adequate.

SECTION 3 - INTRODUCTION TO FOOD SAFETY ASSESSMENT

Unintended Effects

16. Included the expression "and evaluated" after the expression " to be considered, a more detailed information should be assayed/studied".

SECTION 4- GENERAL CONSIDERATIONS

26. It is necessary to include a new footnote to clarify the meaning of insertion sequences. What kind of insertion sequences must be considered in this situation?

  • Include in the second paragraph, after "integrons", the word "super-integrons".

  • "Super-integrons" has been reported a new class of genetic elements1, 2 which might/should be considered in the recipient microorganism.

- 1,The role of integrons in dissemination of antibiotic resistance. Annales de Biologie Clinique. Vol. 58, Issue 4, 439-44, 2000.
- 2 The evolutionary history of chromosomal super-integrons provides an ancestry for multiresistant integrons. Proc. Natl. Acad. Sci. USA: Vol. 98, No. 2, 652657, January 16, 2001.

Safety Assessment

Expressed Substances Including Toxins or Other Traits Related to Pathogenicity

37. In the second paragraph, after the phrase "recombinant-DNA microorganisms", insert the preposition "from" in the beginning the phrase: " the food product if the substance is secreted ".

  • The sentence " the food product if the substance is secreted" without the preposition "from" don´t have a clear meaning, since we don't know if the protein is expressed by the yeast and /or bacteria (alternative source) or produced by the microorganism evaluated.

38. Include in the second bullet after "chronic toxicity/carcinogenicity', the word "mutagenicity".

  • Mutagenicity studies have been reported and currently assayed to evaluate potential toxicity of non-protein substances.

Antibiotic Resistance and Gene Transfer

49. Include "super-integrons" after integrons", since this is a new class of mobile DNA element2, that should be assayed.
- 2 The evolutionary history of chromosomal super-integrons provides an ancestry for multiresistant integrons. Proc. Natl. Acad. Sci. USA: Vol. 98, No. 2, 652657, January 16, 2001.

56. Keep the whole paragraph in square brackets, until appropriate information on the uses of additional conventional foods or food components may be obtained.

General considerations:

  • Evaluation parameters of the proteins expression, metabolites, alergenicity features and residence of the recombinant microorganism in the human digestive tract, besides the influence of the organism in the composition and nutricional aspect and food processing they are appropriate for risk evaluation and food safety.
     

  • Safety Recommendations in the strategy applied for genetics modification are appropriate, including, for example, the necessity to avoid the hosts with transmissible plasmids with antibiotic resistance genes the use of vectors suicides and other systems drawn to assure the non-gene transfer in the host genome.
     
  • Information about the genetic construction should be provided, the stability of the gene(s) inserted will be better acceptable if the same genes were inserted in the microbial chromosome. That condition, particularly to bacterias, should be proposed/demanded.


ANEXO A POSIÇÃO BRASILEIRA PARA A 3ª REUNIÃO DO GRUPO INTERGOVERNAMENTAL AD HOC DO CODEX SOBRE ALIMENTOS DERIVADOS DA BIOTECNOLOGIA

TEMA 7 - Resposta a CL 2001/27 - FBT
Brazilian Delegation Position to be presented in the Course of the Codex Task Force CX-FBT on Traceability

Traceability is being discussed by several Codex Committees besides CX-FBT because this subject exceeds the limits of the discussions of the foods characterized as GMOs or Foods Derived from Modern Biotechnology.

Contrary to the idea sustained by the French Delegation to whom Traceability should be treated as a register system of outstanding value for Risk Analysis of Foods, Brazil considers Treaceability as a system aiming only to provide information concerning the origin, processing and localization of Foods Derived from Modern Biotechnology. This system could be of great importance not only to consumers, but also to producers and market operator agents as well.

The Brazilian Delegation is discussing Traceability from the developing countries point of view, where this issue should be characterized as a voluntary system deprived from a mandatory character. Also, the technical and economical viabilities, the ethic dimension of these issues as well as the existing capabilities of the developing countries to line up and to be able to follow the international guidance, should be taken into consideration.

The Brazilian position regarding the Codex Committees discussions related to Traceability takes into consideration the framework of the Brazilian Biosafety Legislation , which establishes rules of great severity only when there is a risk that threatens human, or animal health, or the environment. The Brazilian Biosafety Legislation establishes priorities and differences regarding the assessment of the risks inherent to foods derived from Modern Biotechnology. For example, the normative rules nº 2 and 4 of the Brazilian Biosafety Legislation establish that if someone is dealing with food or any material considered as category of Risk - "Group 1", there is no need to obtain authorization from the National Technical Biosafety Committee - CTNBio) , but if the food is classified in the category of risk "Group 2" the applicant has to apply to the Committee for permission.

The Brazilian Delegation position presented during the meeting of CX-FBT-Codex helded in Genebra (2-7 of july, 2001) was consistent with our national rules. The Brazilian Committee considered that Traceability, is not a matter of risk, but a question of information to the consumers.
Understanding that this subject should not to be taken as a matter of Risk Analysis, we consider the next points:

  • Traceability is a very important aspect to be consider for foods in general, being a question of food security in certain cases;

  • The subject Traceability exceeds the definition of Foods Derived from Modern Biotechnology;
  • The treatment of this topic have to be uniform in the different Codex Committees, like General Principles, having to be discussed in a hamonized way by the General Commission;
  • It is important to consider the costs of implementation of any mechanism of Traceability, such an effective capacity of the countries to implement certain rules;
  • Finally, respecting our countrie's reality and considering the type of product, the costs and the fiscalization system needed, stay attaint that there is no reason for a mandatory decision for this subject.

In summary, the Brazilian Delegation does not support the inclusion of the Traceability related discussion at this point, as it exceeds the mandate of the FBT.


©2001 ANBio - Associação Nacional de Biossegurança.
All rights reserved.